Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma

Cancer

Volumn 94, Issue 3, 2002, Pages 601-605

  Wilder, Richard B ^a,b   Romaguera, Jorge E ^a   Tucker, Susan L ^a   Ha, Chul S ^a   Hess, Mark A ^a   Cabanillas, Fernando ^a   Cox, James D ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Non Hodgkin lymphoma; Surgery

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; LYMPHOMA; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; SURGICAL APPROACH;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, HIGH-GRADE; LYMPHOMA, INTERMEDIATE-GRADE; MALE; MIDDLE AGED; PREDNISONE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0036468437     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10260     Document Type: Article

References (20)

1. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project
2. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
3. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma
4. Bulk of tumour as an important prognostic factor in non-Hodgkin's lymphoma
5. Diffuse large cell lymphoma. Prognostic factors with treatment
6. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy
7. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study
8. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma
9. Large-cell lymphoma: A study of prognostic factors and assessment of five recently proposed predictive systems
10. Dose-response analysis for radiotherapy delivered to patients with intermediate grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy
11. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
12. Nonparametric estimation from incomplete observations
13. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
14. The design and interpretation of clinical trials
15. Predictive model for prognosis in advanced diffuse histiocytic lymphoma
16. Thyroid lymphoma: Is there a role for surgery?
17. Surgical debulking is associated with improved survival in Stage I-II diffuse large cell lymphoma
18. Stages I and II non-Hodgkin's lymphoma of the gastrointestinal tract. Retrospective analysis of 79 patients and review of the literature
19. Stomach conservation in Stages IE and IIE gastric non-Hodgkin's lymphoma
20. Lymphomas of the cervix and upper vagina: A report of five cases and a review of the literature